For asymptomatic patients with saline implants, no imaging is recommended. If there is suspected saline implant rupture, ultrasound is usually appropriate, though saline implant rupture is often clinically evident. For asymptomatic patients with silicone implants, the FDA recommends that patients have an initial ultrasound or MRI examination without contrast 5 to 6 years after initial silicone implant surgery and then every 2 to 3 years thereafter. In a patient with silicone implants and suspected implant complication, MRI without contrast is usually appropriate and ultrasound and/or mammography may be appropriate, depending on age. In a patient with unexplained axillary adenopathy with current or prior silicone breast implants, ultrasound and/or mammography are usually appropriate, depending on age. In the setting of a patient with breast implants of any type and suspected implant-associated malignancy, ultrasound or MRI without and with contrast is usually appropriate as initial imaging test. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Breast cancer screening recommendations have been established historically for women, but, have been less clearly outlined for men. For average-risk men and younger men less than 25 year of age, imaging is not usually appropriate as a screening test for breast cancer. For men of higher-than-average risk, screening with mammography as annual surveillance imaging is usually appropriate. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Routine screening substantially reduces the risk of mortality and morbidity of breast cancer with early detection. Multiple different imaging modalities may be used to screen for breast cancer. Screening recommendations differ based on an individual's risk of developing breast cancer. Numerous factors contribute to breast cancer risk, which is frequently divided into three major categories: average, intermediate, and high risk. For patients assigned female at birth with native breast tissue, mammography and digital breast tomosynthesis are recommended for breast cancer screening in all risk categories. In high-risk patients, screening with breast MRI is recommended starting as early as 25 to 30 years of age and mammography and digital breast tomosynthesis with a variable starting age between 25 and 40 years of age, depending on the type of risk. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Effective follow-up care plays a critical role in enhancing breast cancer outcomes, as diagnosing breast cancer in earlier stages can improve mortality and ease treatment burden. Individuals with unmet social needs face greater barriers in completing their follow-up care (e.g., additional imaging, biopsies, and surgery). They are two times less likely to complete follow-up appointments. When patients do not complete follow-up appointments, they are at higher risk of detecting breast cancer at a later stage. We aim to examine how a social needs intervention via community navigation may (1) address patients’ social needs, and (2) improve the completion of recommended medical care following an abnormal mammography. This is a single-center randomized controlled trial taking place in the Intermountain West. We plan to enroll 1,450 participants throughout the study. Women with abnormal mammography results will be invited to complete a validated, 10-item social needs screening assessment in English or Spanish. Eligible patients will be at least 18 years of age, speak English or Spanish, and indicate at least one social need. Participants will be randomized to passive or active social needs categories. Those in the active group will be called by 211 United Way services (211), a service which connects callers to community resources. The passive group will not receive a call from 211. Instead, they will be provided with information to contact 211 independently if they choose to. Primary outcomes are: (1) change in social needs, and (2) follow-up of abnormal mammography results, and will be assessed through follow-up surveys and chart reviews. Interviews and focus group discussions will explore how social needs influence patients’ adherence to recommended follow-up after an abnormal mammography result, and the role of community service navigation assistance in that follow-up. This study utilizes a 10-item social needs assessment and community navigation services to address social needs that prevent women from receiving timely follow-up after an abnormal mammogram screening. Our goal is to improve breast cancer follow-up outcomes for women with social needs. The study was pre-registered at ClinicalTrials.gov on March 12, 2024, under identifier NCT06305312.

Early detection of breast cancer from regular screening substantially reduces breast cancer mortality and morbidity. Multiple different imaging modalities may be used to screen for breast cancer. Screening recommendations differ based on an individual’s risk of developing breast cancer. Numerous factors contribute to breast cancer risk, which is frequently divided into three major categories: average, intermediate, and high risk. For patients assigned female at birth with native breast tissue, mammography and digital breast tomosynthesis are the recommended method for breast cancer screening in all risk categories. In addition to the recommendation of mammography and digital breast tomosynthesis in high-risk patients, screening with breast MRI is recommended.The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Introduction: Lifestyle change programs (LCPs) are effective in helping people adopt healthy lifestyles and maintain healthy weight for disease prevention. LCPs are known to be underutilized, but the nuances surrounding women's interest in using these programs for disease prevention need to be further explored so that enrollment and retention in these programs can be improved.Methods: The purpose of this study was to explore women's interest in and knowledge of LCPs and identify their motivators and barriers to joining these types of programs through a survey. The survey was administered both online and in person. The survey had 22 questions and included demographics, medical and family history, knowledge and interest in LCPs, and barriers and motivators to participating in LCPs.Results: Participants in this study included 1,606 women from 40 to 74 years of age. We found that respondents had limited knowledge about the benefits of LCPs in reducing risks of specific diseases, such as breast cancer and osteoarthritis. Respondents reported low-to-moderate interest in LCPs. We found that their interest in these programs was negatively associated with their weekly physical activity and positively associated with their body mass index (BMI) and the number of reported barriers to joining LCPs. The most common barriers cited were cost, location, time, and too many meetings. In addition, we found that respondents who had or were unsure about their family history of diabetes were more interested in LCPs compared with individuals who had no family history of diabetes. We did not find significant differences in respondent interest in LCPs across ethnicity.Conclusions: Our study suggests that specific barriers to LCPs-including women's knowledge of such programs-will need to be addressed before enrollment and retention in LCPs are increased.

Objective:Given variability in how practices manage patients on antithrombotic medications, we undertook this study to understand the current practice of antithrombotic management for patients undergoing percutaneous breast and axillary procedures. Methods:A 20-item survey with multiple-choice and write-in options was emailed to 2094 active North American members of the Society of Breast Imaging (SBI) in March 2021. Data were collected anonymously and analyzed quantitatively, with free-text responses categorized by themes. Results:Three-hundred twenty-six of 2094 members (15.6%) completed the survey. Eighty-seven percent (274/313) reported having a policy for managing antithrombotic medications. Fifty-nine percent (185/312) reported routinely withholding medications before biopsy, more commonly in the Northeast and South (P = 0.08). Withholding of medications did not vary by lesion location (182/308, 59%, breast vs 181/308, 58.7%, axillary; P = 0.81). Respondents were statistically more likely to withhold medications if using a vacuum-assisted device for all classes of antithrombotic medications (P < 0.001). Up to 50.2% (100/199) on warfarin and 33.6% (66/196) on direct oral anticoagulants had medications withheld more stringently than guidelines suggest. Conclusion:Based on a survey of SBI members, breast imaging practices vary widely in antithrombotic management for image-guided breast and axillary procedures. Of the 60% who withhold antithrombotic medications, a minority comply with recommended withhold guidelines, placing at least some patients at potential risk for thrombotic events. Breast imaging radiologists should weigh the risks and benefits of withholding these medications, and if they elect to withhold should closely follow evidence-based guidelines to minimize the risks of this practice.

Palpable masses in women are the most common symptom associated with breast cancer. This document reviews and evaluates the current evidence for imaging recommendations of palpable masses in women less than 30 to over 40 years of age. There is also a review of several different scenarios and recommendations after initial imaging. Ultrasound is usually the appropriate initial imaging for women under 30 years of age. If ultrasound findings are suspicious or highly suggestive of malignancy (BIRADS 4 or 5), it is usually appropriate to continue with diagnostic tomosynthesis or mammography with image-guided biopsy. No further imaging is recommended if the ultrasound is benign or negative. The patient under 30 years of age with a probably benign ultrasound may undergo further imaging; however, the clinical scenario plays a role in the decision to biopsy. For women between 30 to 39 years of age, ultrasound, diagnostic mammography, tomosynthesis, and ultrasound are usually appropriate. Diagnostic mammography and tomosynthesis are the appropriate initial imaging for women 40 years of age or older, as ultrasound may be appropriate if the patient had a negative mammogram within 6 months of presentation or immediately after mammography findings are suspicious or highly suggestive of malignancy. If the diagnostic mammogram, tomosynthesis, and ultrasound findings are probably benign, no further imaging is necessary unless the clinical scenario indicates a biopsy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Objective Conflicting data exist on the diagnostic sensitivity of core-needle biopsy (CNB) compared to fine-needle aspiration (FNA) in the evaluation of axillary lymph node metastasis from breast cancer. Our purpose was to evaluate the sensitivity of CNB and FNA using subsequent axillary surgery as the gold standard and to compare the patients’ subjective pain levels for each biopsy method. Methods This IRB-approved prospective study enrolled 140 patients from February 2014 to May 2019 with known or suspected breast cancer. Patients underwent both US-guided FNA and 14-gauge CNB of the same node with clip placement and rated their pain level using a verbal numerical rating scale of 0 to 10. The diagnostic sensitivities were determined by pathology of the surgically excised lymph node using the McNemar test of correlated proportions. Changes in pain scores for CNB and FNA were determined using the Wilcoxon rank sum test. Results A total of 94 patients had confirmatory excision of the biopsied node with nodal metastasis detected in 71.3% (67/94). The sensitivity of CNB for detection of nodal metastasis was 95.5% (64/67), while the sensitivity of FNA was 67.2% (45/67) (P < 0.05). Overall pain score ratings for CNB increased by 0.6 from baseline on an 11-point numerical rating scale, while overall pain score rating for FNA decreased by 0.2 from baseline (P < 0.05). Conclusion Our study demonstrates that 14-gauge CNB has superior sensitivity for detection of axillary nodal metastases and mildly increased pain compared with 25-gauge FNA in patients with breast cancer.

10531 Background: A breast cancer (BC) that emerges following a negative/benign screening mammogram (SMG) but before the next expected SMG is referred to as an interval breast cancer (IBC). Current guidelines vary in the recommended frequency of SMG: some guidelines support SMG every 12 months, others every 24 months, and many adapt the 12- or 24-month recommendation by age. This study compared the clinical characteristics of IBC that developed within a 3-12 month interval (12m IBC) and a 13-24 month interval (24m IBC) in a statewide population. Methods: This is a retrospective cohort study using demographic/medical records in the Utah Population Database linked to the Utah Cancer Registry, a Surveillance, Epidemiology, and End Results (SEER) registry. Index SMG refers to the SMG just prior to a diagnostic mammogram or other clinical encounter, which led to a BC diagnosis before the next, expected SMG. Women ages ≥38y who underwent SMG during 2005-2019 at Intermountain Healthcare and University of Utah Health, had no history of BC prior to first SMG, and had BI-RADS assessment of normal or benign finding at index SMG were included. Clinical characteristics of 12m IBC and 24m IBC were compared using multivariable logistic regression to provide odds ratio estimates with covariate adjustment for age at diagnosis, stage, tumor size, grade, histology, biomarkers, breast density, body mass index, family history of breast cancer, and age at first birth. Women who developed IBC during the 3-12 month interval were not counted in the 24m IBC group. Results: A total of 7776 BC were observed in this study, among which 2122 were IBC; 486 (6.3%) 12m IBC and 1636 (21.0%) 24m IBC. Women with 12m IBC and 24m IBC had similar rates of a first-degree family history of breast cancer (16% and 17%, respectively). Women 70 and older were the least likely to develop IBC in 12 months as compared to 24 months (OR 2.34, 95% CI: 1.61-3.40, p< 0.01). The odds of having axillary lymph node metastases (regional disease) at the time of BC diagnosis was higher among 12m IBC than 24m IBC (OR 1.68, 95% CI: 1.29-2.19, p< 0.01). A total of 41 women with IBC had distant metastatic disease at the time of diagnosis (5% 12m IBC, 1% 24m IBC). Among those, the odds that metastatic IBC would be a 12m IBC were significantly higher than 24m IBC (OR = 4.07, CI 2.03-8.29, p< 0.01). The 12m IBC group was more likely to be HER2 positive (OR 2.10, 95% CI: 1.36-3.22, p< 0.01) or triple negative (OR 2.08, 95% CI: 1.26-3.39, p< 0.01) than the 24m IBC group. Extremely dense breast tissue at SMG increased the odds of developing 12m IBC compared to 24m IBC (OR 2.05, 95% CI: 1.13-3.80, p< 0.01). Conclusions: Compared to 24m IBC, 12m IBC appeared to be more advanced and aggressive. Women with Extremely dense breast tissue were more likely to develop 12m IBC than 24m IBC. These results suggest that women with extremely dense breast tissue or age < 70y may benefit from annual SMG instead of biennial SMG.

OBJECTIVES:To assess perceptions among breast radiologists regarding optimal breast imaging rotation organization and educational activities for radiology residents.METHODS:An IRB-exempt anonymous questionnaire was developed in REDCap and distributed as a member survey email by the Society of Breast imaging to 2188 members June 2019. A form with 33 questions asked questions about opinions related to resident rotation composition, read-out strategies, study/procedure volume, simulation and educational materials specific to breast imaging.RESULTS:A total of 109/2,188 (4.98%) complete survey responses were received. Of the responders, 69/109 (62%) work in academic practice, 16/109 (15%) work in private practice with residents, and 24/109 (22%) work in private practice without residents. There was no significant variation in opinion between those who have >10 years of experience teaching breast imaging 49/109(42.2%) to those with less <10 years' experience 60/109 (55%). A range of opinions is demonstrated regarding the multiple questions asked with more support for diagnostics and procedures on the second and thirds rotations compared to first rotations. There was strong support of in-person staffing, checklists, simulation for ultrasound-guided procedures (91%) and formal training on delivering bad news (90%). Radiology-pathology conferences and faculty-developed teaching files were highest-rated for effective educational tools.CONCLUSIONS:The results from this survey show varied opinions regarding perceived best practices for resident breast radiology rotations . Further research is needed to determine training outcomes related to rotation organization. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Breast tumor segmentation is a critical task in computer-aided diagnosis (CAD) systems for breast cancer detection because accurate tumor size, shape, and location are important for further tumor quantification and classification. However, segmenting small tumors in ultrasound images is challenging due to the speckle noise, varying tumor shapes and sizes among patients, and the existence of tumor-like image regions. Recently, deep learning-based approaches have achieved great success in biomedical image analysis, but current state-of-the-art approaches achieve poor performance for segmenting small breast tumors. In this paper, we propose a novel deep neural network architecture, namely the Enhanced Small Tumor-Aware Network (ESTAN), to accurately and robustly segment breast tumors. The Enhanced Small Tumor-Aware Network introduces two encoders to extract and fuse image context information at different scales, and utilizes row-column-wise kernels to adapt to the breast anatomy. We compare ESTAN and nine state-of-the-art approaches using seven quantitative metrics on three public breast ultrasound datasets, i.e., BUSIS, Dataset B, and BUSI. The results demonstrate that the proposed approach achieves the best overall performance and outperforms all other approaches on small tumor segmentation. Specifically, the Dice similarity coefficient (DSC) of ESTAN on the three datasets is 0.92, 0.82, and 0.78, respectively; and the DSC of ESTAN on the three datasets of small tumors is 0.89, 0.80, and 0.81, respectively.

Given that 20% to 40% of women who have percutaneous breast biopsy subsequently undergo breast surgery, knowledge of imaging women with a history of benign (including high-risk) disease or breast cancer is important. For women who had surgery for nonmalignant pathology, the surveillance recommendations are determined by their overall risk. Higher-than-average risk women with a history of benign surgery may require screening mammography starting at an earlier age before 40 and may benefit from screening MRI. For women with breast cancer who have undergone initial excision and have positive margins, imaging with diagnostic mammography or MRI can sometimes guide additional surgical planning. Women who have completed breast conservation therapy for cancer should get annual mammography and may benefit from the addition of MRI or ultrasound to their surveillance regimen. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances in which peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.

Autologous fat grafting (AFG) is a technique that is increasingly utilized in breast cosmetic and reconstructive surgery. In this procedure, fat is aspirated by liposuction from one area of the body and injected into the breast. The procedure and process of AFG has evolved over the last few decades, leading to more widespread use, though there is no standard method. Autologous fat grafting is generally considered a safe procedure but may result in higher utilization of diagnostic imaging due to development of palpable lumps related to fat necrosis. Imaging findings depend on surgical technique but typically include bilateral, symmetric, retromammary oil cysts and scattered dystrophic and/or coarse calcifications when AFG is used for primary breast augmentation. More focal findings occur when AFG is used to improve specific areas of cosmetic deformity, scarring, or pain following breast cancer surgery. As with any cause of fat necrosis, imaging features tend to appear more benign over time, with development of rim calcifications associated with oil cysts and a shift in echogenicity of oil cyst contents on ultrasound towards anechoic in some cases. This article reviews the AFG procedure, uses, complications, and imaging findings.

"Starting in Wuhan, China, followed quickly in the United States in January 2020, an outbreak of a novel coronavirus, or COVID-19, escalated to a global pandemic by March. Significant disruptions occurred to breast imaging, including deferred screening mammography, triaging diagnostic breast imaging, and changes in breast cancer care algorithms. This article summarizes the effect of the global pandemic-and efforts to curtail its spread-on both breast cancer care and on breast imaging practices including effects on patients, clinical workflow, education, and research."

Incorporating human domain knowledge for breast tumor diagnosis is challenging because shape, boundary, curvature, intensity or other common medical priors vary significantly across patients and cannot be employed. This work proposes a new approach to integrating visual saliency into a deep learning model for breast tumor segmentation in ultrasound images. Visual saliency refers to image maps containing regions that are more likely to attract radiologists' visual attention. The proposed approach introduces attention blocks into a U-Net architecture and learns feature representations that prioritize spatial regions with high saliency levels. The validation results indicate increased accuracy for tumor segmentation relative to models without salient attention layers. The approach achieved a Dice similarity coefficient (DSC) of 90.5% on a data set of 510 images. The salient attention model has the potential to enhance accuracy and robustness in processing medical images of other organs, by providing a means to incorporate task-specific knowledge into deep learning architectures.

Abstract Introduction: Women with extremely dense breast tissue on mammography have a higher risk of breast cancer compared to similarly-aged women with less dense breast tissue. Tamoxifen therapy has been observed to reduce breast density among both pre- and postmenopausal women with HR+ breast cancer and may predict benefit of therapy. Studies of aromatase inhibitor (AI) therapy and breast density change, however, are limited and results inconclusive. Factors associated with breast density change with ET, and effect of duration of ET on breast density change, have not been well studied. Methods: Using the Utah Population Database, women were identified who underwent screening mammography in 2005-2016 and who had no personal history of breast cancer. Those who were subsequently diagnosed with HR+ breast cancer and treated in one of the major health care systems in Utah (Intermountain Healthcare or University of Utah Health) were included in the analysis. ET prescription information and duration of ET were obtained from provider records and the Utah All-Payer Claims Database. Women with mammography results in the electronic medical record both before and within 3 years after the breast cancer diagnosis were included. BI-RADS density classification from mammogram reports 6-12 months, 13-24 months, and 25-36 months after ET initiation were compared to pre-diagnosis BI-RADS density classification. Breast density reduction was defined as a decrease of ≥1 BI-RADS category compared to baseline. Fisher’s exact test was used to examine ET and breast density reduction among women ≥55y and <55y. Results: In total, 1328 women with HR+ breast cancer and baseline BI-RADS breast density categories B-D were included. Women with BI-RADS density category A(almost entirely fatty) were excluded. A majority (61%) were age ≥55y at diagnosis, were non-Hispanic white (90%), and had BMI ≥25 kg/m2 (56%); 15% had a first-degree family history of breast cancer. At baseline, 602 (44%) women had scattered fibroglandular densities (BI-RADS category B), 697 (50%) had heterogeneously dense breasts (BI-RADS category C), and 83 (6%) had extremely dense breasts (BI-RADS category D). Half were treated with AI only (49%), 21% with tamoxifen only, and 29% with both during follow-up. In both the age ≥55y and <55y groups, women with BI-RADS category D at baseline were more likely to experience a reduction in breast density with ET compared to women with either BI-RADS categories B or C (Table 1). There were no significant differences in breast density reduction observed between women treated with AI only compared to those treated with tamoxifen only, irrespective of age and baseline density. Breast cancer family history also had no effect on breast density reduction with ET. Conclusion: Baseline breast density is associated with a demonstrable reduction in breast density during ET. Our findings suggest that AI therapy can reduce breast density similar to that seen with tamoxifen therapy. Table 1 Breast Density (BD) changes among women who underwent mammography 6-12 months, 13-24 months, and 25-36 months after ET initiationBaseline BDN≥55 years oldPTotal<55 years oldPNo BD reduction N(%)BD reduction N(%)No BD reduction N(%)BD reduction N(%)6-12 months after ET initiationScattered157152(97)5(3)5452(96)2(3)Heterogeneous148115(78)33(22)10477(74)27(26)Dense144(29)10(71)<0.0001248(33)16(67)<0.0001Total319271(85)48(15)182137 (75)45(25)13-24 months after ET initiationScattered232214(92)18(8)8473(87)11(13)Heterogeneous211144(68)67(32)155107(69)48(31)Dense172(12)15(88)<0.0001287(25)21(75)<0.0001Total460360(78)100(22)267187(70)80(30)25-36 months after ET initiationScattered248220(89)28(11)8374(89)9 (11)Heterogeneous203133(66)70(35)16097(61)63(39)Dense162(13)14(88)<0.00013213(41)19 (59)<0.0001Total467355(76)112(24)275184(67)91(33) Citation Format: Mei Wei, Lisa Pappas, Emily Guinto, Carol Sweeney, Nicola Camp, Phoebe Freer, Saundra Buys, N. Lynn Henry, Karen Curtin. Mammographic breast density changes with endocrine therapy (ET) in women with hormone receptor positive (HR+) breast cancer in a Utah population [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-10.